Sanofi (NASDAQ:SNY) Shares Acquired by Invesco Ltd.

Invesco Ltd. lifted its stake in Sanofi (NASDAQ:SNY) by 3.5% in the fourth quarter, HoldingsChannel reports. The firm owned 12,059,283 shares of the company’s stock after purchasing an additional 408,752 shares during the period. Invesco Ltd.’s holdings in Sanofi were worth $581,619,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Synergy Asset Management LLC purchased a new stake in shares of Sanofi in the 4th quarter valued at approximately $25,000. McClarren Financial Advisors Inc. boosted its position in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after buying an additional 543 shares during the period. Lee Danner & Bass Inc. purchased a new position in shares of Sanofi during the fourth quarter valued at $31,000. Sunbelt Securities Inc. grew its holdings in shares of Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after buying an additional 313 shares in the last quarter. Finally, Sierra Ocean LLC acquired a new position in Sanofi during the fourth quarter valued at $44,000. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on SNY shares. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. The Goldman Sachs Group initiated coverage on shares of Sanofi in a report on Friday, March 21st. They set a “neutral” rating and a $65.00 price target on the stock. Finally, StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Three equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $62.50.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $50.76 on Tuesday. The business’s 50 day moving average is $55.32 and its 200-day moving average is $52.60. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $128.82 billion, a PE ratio of 20.39, a PEG ratio of 1.01 and a beta of 0.57. Sanofi has a 1-year low of $45.22 and a 1-year high of $60.12.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sell-side analysts predict that Sanofi will post 4.36 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.